<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21730">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01950312</url>
  </required_header>
  <id_info>
    <org_study_id>X052180</org_study_id>
    <secondary_id>R33DC011827</secondary_id>
    <nct_id>NCT01950312</nct_id>
  </id_info>
  <brief_title>The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease</brief_title>
  <official_title>An Open-label Study of the Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XOMA (US) LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Feinstein Institute for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>XOMA (US) LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if gevokizumab therapy may be an alternate therapy
      in patients with steroid resistant Autoimmune Inner Ear Disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improved hearing threshold, as defined by an improvement in either the PTA (Pure Tone Average) of &gt;=5 dB (Decibel), or 12% in the WRS (Word Recognition Score)</measure>
    <time_frame>Day 28 to Day 84</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Autoimmune Inner Ear Disease</condition>
  <arm_group>
    <arm_group_label>gevokizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gevokizumab</intervention_name>
    <arm_group_label>gevokizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Autoimmune Inner Ear Disease with active deterioration in at least one ear

          -  Failure to respond to a trial of high-dose corticosteroid therapy

          -  Contraceptive measures adequate to prevent pregnancy during the study

        Exclusion Criteria:

          -  Evidence of retrocochlear pathology (vestibular schwannoma) or inner ear malformation
             (Mondini Malformation or Enlarged Vestibular Aqueduct)

          -  History of active or chronic infections

          -  Currently receiving, or having received treatment for a malignancy in the past three
             years

          -  Hearing loss that coincides with significant, disabling episodes of vertigo

          -  History of allergic or anaphylactic reactions to monoclonal antibodies

          -  Female subjects who are pregnant, planning to become pregnant, have recently
             delivered, or are breast-feeding

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center, Hearing &amp; Speech Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Vambutas, MD</last_name>
      <phone>718-470-7550</phone>
    </contact>
    <contact_backup>
      <last_name>Ginny Mullooly</last_name>
      <phone>718-470-7974</phone>
    </contact_backup>
    <investigator>
      <last_name>Andrea Vambutas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 20, 2013</lastchanged_date>
  <firstreceived_date>September 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune Inner Ear Disease</keyword>
  <keyword>Inner Ear Disease</keyword>
  <keyword>Meniere's Disease</keyword>
  <keyword>Sudden Sensorineural Hearing Loss</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ear Diseases</mesh_term>
    <mesh_term>Labyrinth Diseases</mesh_term>
    <mesh_term>Labyrinthitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
